Sanofi Net Acquisitions/Divestitures 2012-2026 | SNY
Sanofi annual/quarterly net acquisitions/divestitures history and growth rate from 2012 to 2026. Net acquisitions/divestitures can be defined as the total change in cash resulting from both investments in businesses and sales of businesses or business segments.
- Sanofi net acquisitions/divestitures for the quarter ending March 31, 2026 were $0M, a 0% increase year-over-year.
- Sanofi net acquisitions/divestitures for the twelve months ending March 31, 2026 were $23.922B, a 20381.88% decline year-over-year.
- Sanofi annual net acquisitions/divestitures for 2024 were $-0.118B, a 0% decline from 2023.
- Sanofi annual net acquisitions/divestitures for 2023 were $0B, a 0% decline from 2022.
- Sanofi annual net acquisitions/divestitures for 2022 were $0B, a 0% decline from 2021.
|
Sanofi Annual Net Acquisitions/Divestitures (Millions of US $) |
|
|---|---|
| 2024 | $-118 |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | $11,846 |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
| 2015 | N/A |
| 2014 | N/A |
| 2013 | N/A |
| 2012 | N/A |
| 2011 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $114.048B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |